Provexis plc
Provexis plc is an AIM-listed (PXS) UK company that discovers, develops and commercialises functional food, medical food and dietary supplement technologies, centred on its patented Fruitflow heart-health ingredient (a natural anti-platelet extract from tomatoes). Fruitflow is sold as an ingredient to brand owners via former DSM customers, direct customers, and a long-term supply and distribution agreement with BYHEALTH Co., Ltd for the Chinese market; the group also sells a direct-to-consumer Fruitflow+ Omega-3 dietary supplement. The group has been loss-making since inception and is funded exclusively by equity capital.
FY2026 in sixty seconds
year to 31 Mar 2026 · approved 30 Sept 2026 · 58 pages · Companies House
Provexis plc sells Fruitflow, a heart-health ingredient made from tomatoes, to food and supplement brands. In the year to 31 March 2026 revenue was £1.3m, down 2.1% on the previous year's £1.3m, and the loss before tax widened to £507k from £450k. Sales were broadly flat, with record sales of more than £900k in the second half after a new production run. The bigger loss came mainly from a non-cash charge for share awards, which rose to £308,587 from £168,317, while research and patent costs fell.
Cash at the year end was £893k, up from £708k, and the company has no borrowings. No new shares were sold during the year and no dividend is proposed.
Management expects sales for the six months to 30 September 2026 of more than £1.05m, against £364k a year earlier, and hopes for a new health claim in China. However, the auditor warned of a material uncertainty over the company's future, as it may need to raise more money to keep going, though its audit opinion was not qualified.
Fruitflow II SD ingredient sales to former DSM customers, direct customers and the BYHEALTH China supply/distribution agreement
Revenue of £1,148,623 (2025: £1,170,939) from Fruitflow II SD ingredient; principal sales channels listed as former DSM customers, DSM Premix/Market-Ready business, new direct customers, and BYHEALTH
page 12DSM royalty on gross profits from transferred customers, payable within cost of goods until it ceases on 1 January 2027
Royalty payable to DSM on gross profits generated from Fruitflow sales to customers transferred from DSM over four years from 1 Jan 2023; FY2026 included nine months at the third-year rate and three months at the lower final (fourth) year rate; royalties cease from 1 January 2027
page 13The Company expects that (i) the significant changes to the sales and supply chain structure for Fruitflow from January 2023, (ii) the gut microbiome patent application and related long-term partnership with DSM and (iii) the recent BYHEALTH regulatory developments in China will have a strongly beneficial effect on the current and future commercial prospects for Fruitflow and the business worldwide.
page 10The Directors are unable to recommend the payment of a dividend (2025: £Nil), consistent with the Group's continued losses and cash conservation stance.
page 1412 years on one page · FY2015–FY2026
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY2023locked | FY202403/24 | FY202503/25 | FY202603/26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Operating profit | ||||||||||||
| Profit for the year | ||||||||||||
| Basic EPS | ||||||||||||
| Free cash flow | ||||||||||||
| Net debt (negative = net cash) | ||||||||||||
| Shares in issue | ||||||||||||
| Operating margin | ||||||||||||
| Return on capital employed | — |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
Nothing restated
Every figure is read again from the following year’s report: 292 confirmed, 12 differ.
No figure has been restated: every figure a later report printed again, it printed the same.